{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T15:10:28Z","timestamp":1728918628591},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,14]]},"DOI":"10.7759\/cureus.71439","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T14:28:14Z","timestamp":1728916094000},"source":"Crossref","is-referenced-by-count":0,"title":["Mirtazapine: A One-Drug Intervention for the Physical and Psychological Symptoms of End-Stage Renal Disease (ESRD)"],"prefix":"10.7759","author":[{"given":"Onyinyechi V","family":"Evoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Totini","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukaila","family":"Raji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"O'Mahony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"End-stage renal disease","author":"Hashmi MF","year":"2023","unstructured":"Hashmi MF, Benjamin O, Lappin SL. End-stage renal disease. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref2","unstructured":"United Network for Organ Sharing. (2024). Accessed. April 11, 2024: https:\/\/unos.org\/."},{"key":"ref3","unstructured":"National Center for Biotechnology Information (2024). PubChem compound summary for CID 4205, mirtazapine. (2024). Accessed. April 23, 2024: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Mirtazapine."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-019-02121-5","article-title":"Treating symptoms to improve the quality of life in patients on chronic hemodialysis","volume":"51","author":"Bossola M","year":"2019","unstructured":"Bossola M, Pepe G, Picca A, Calvani R, Marzetti E. Treating symptoms to improve the quality of life in patients on chronic hemodialysis. Int Urol Nephrol. 2019, 51:885-7. 10.1007\/s11255-019-02121-5","journal-title":"Int Urol Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0269216308101099","article-title":"Symptom burden and quality of life in end-stage renal disease: a study of 179 patients on dialysis and palliative care","volume":"23","author":"Yong DS","year":"2009","unstructured":"Yong DS, Kwok AO, Wong DM, Suen MH, Chen WT, Tse DM. Symptom burden and quality of life in end-stage renal disease: a study of 179 patients on dialysis and palliative care. Palliat Med. 2009, 23:111-9. 10.1177\/0269216308101099","journal-title":"Palliat Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.07.003","article-title":"Undertreatment of symptoms in patients on maintenance hemodialysis","volume":"39","author":"Claxton RN","year":"2010","unstructured":"Claxton RN, Blackhall L, Weisbord SD, Holley JL. Undertreatment of symptoms in patients on maintenance hemodialysis. J Pain Symptom Manage. 2010, 39:211-8. 10.1016\/j.jpainsymman.2009.07.003","journal-title":"J Pain Symptom Manage"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43821","article-title":"Mirtazapine: a one-stop strategy for treatment of opioid withdrawal symptoms","volume":"15","author":"Lalani E","year":"2023","unstructured":"Lalani E, Menon R, Mufti MA, Kumfa C, Raji M. Mirtazapine: a one-stop strategy for treatment of opioid withdrawal symptoms. Cureus. 2023, 15:e43821. 10.7759\/cureus.43821","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K131","article-title":"Mirtazapine for depression and comorbidities in older patients with cancer","volume":"41","author":"Raji MA","year":"2007","unstructured":"Raji MA, Barnum PD, Freeman J, Markowitz AB. Mirtazapine for depression and comorbidities in older patients with cancer. Ann Pharmacother. 2007, 41:1548-9. 10.1345\/aph.1K131","journal-title":"Ann Pharmacother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70182-0","article-title":"Management of chemotherapy-induced side-effects","volume":"6","author":"Raji MA","year":"2005","unstructured":"Raji MA. Management of chemotherapy-induced side-effects. Lancet Oncol. 2005, 6:357-10. 10.1016\/S1470-2045(05)70182-0","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10371","article-title":"Mirtazapine for treatment of depression and comorbidities in Alzheimer disease","volume":"35","author":"Raji MA","year":"2001","unstructured":"Raji MA, Brady SR. Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Ann Pharmacother. 2001, 35:1024-7. 10.1345\/aph.10371","journal-title":"Ann Pharmacother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006528.pub2","article-title":"Mirtazapine versus other antidepressive agents for depression","author":"Watanabe N","year":"2011","unstructured":"Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011, CD006528. 10.1002\/14651858.CD006528.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12051108","article-title":"Uremic pruritus: from diagnosis to treatment","volume":"12","author":"Cheng AY","year":"2022","unstructured":"Cheng AY, Wong LS. Uremic pruritus: from diagnosis to treatment. Diagnostics (Basel). 2022, 12:1108. 10.3390\/diagnostics12051108","journal-title":"Diagnostics (Basel)"},{"key":"ref13","article-title":"Uremic pruritus evaluation and treatment","author":"Osakwe N","year":"2023","unstructured":"Osakwe N, Hashmi MF. Uremic pruritus evaluation and treatment. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s0885-3924(02)00645-0","article-title":"Mirtazapine for pruritus","volume":"25","author":"Davis MP","year":"2003","unstructured":"Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J Pain Symptom Manage. 2003, 25:288-91. 10.1016\/s0885-3924(02)00645-0","journal-title":"J Pain Symptom Manage"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-020-02473-3","article-title":"Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study","volume":"52","author":"Gholyaf M","year":"2020","unstructured":"Gholyaf M, Sheikh V, Yasrebifar F, Mohammadi Y, Mirjalili M, Mehrpooya M. Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study. Int Urol Nephrol. 2020, 52:1155-65. 10.1007\/s11255-020-02473-3","journal-title":"Int Urol Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.025","article-title":"Use of oral antidepressants in patients with chronic pruritus: a systematic review","volume":"77","author":"Kouwenhoven TA","year":"2017","unstructured":"Kouwenhoven TA, van de Kerkhof PC, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: a systematic review. J Am Acad Dermatol. 2017, 77:1068-73. 10.1016\/j.jaad.2017.08.025","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100458","article-title":"Insomnia and poor sleep in CKD: a systematic review and meta-analysis","volume":"4","author":"Tan LH","year":"2022","unstructured":"Tan LH, Chen PS, Chiang HY, et al.. Insomnia and poor sleep in CKD: a systematic review and meta-analysis. Kidney Med. 2022, 4:100458. 10.1016\/j.xkme.2022.100458","journal-title":"Kidney Med"},{"key":"ref18","article-title":"Dose-dependent sedating and stimulating effects of mirtazapine","volume":"19","author":"Leonard SD","year":"2015","unstructured":"Leonard SD, Karlamangla A. Dose-dependent sedating and stimulating effects of mirtazapine. Proc UCLA Health. 2015, 19:","journal-title":"Proc UCLA Health"},{"key":"ref19","article-title":"The effects of mirtazapine on sleep in patients with major depressive disorder","volume":"24","author":"Dolder CR","year":"2012","unstructured":"Dolder CR, Nelson MH, Iler CA. The effects of mirtazapine on sleep in patients with major depressive disorder. Ann Clin Psychiatry. 2012, 24:215-24.","journal-title":"Ann Clin Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s005200000215","article-title":"Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy","volume":"9","author":"Kast RE","year":"2001","unstructured":"Kast RE. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer. 2001, 9:469-70. 10.1007\/s005200000215","journal-title":"Support Care Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200010000-00006","article-title":"Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens","volume":"20","author":"Radhakishun FS","year":"2000","unstructured":"Radhakishun FS, van den Bos J, van der Heijden BCJM, Roes KCB, O'Hanlon JF. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol. 2000, 20:531-7. 10.1097\/00004714-200010000-00006","journal-title":"J Clin Psychopharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ackd.2005.03.008","article-title":"Chronic pain in end-stage renal disease","volume":"12","author":"Davison SN","year":"2005","unstructured":"Davison SN. Chronic pain in end-stage renal disease. Adv Chronic Kidney Dis. 2005, 12:326-34. 10.1016\/j.ackd.2005.03.008","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/s0885-3924(99)00098-6","article-title":"The use of mirtazapine in a patient with chronic pain","volume":"18","author":"Brannon GE","year":"1999","unstructured":"Brannon GE, Stone KD. The use of mirtazapine in a patient with chronic pain. J Pain Symptom Manag. 1999, 18:382-5. 10.1016\/s0885-3924(99)00098-6","journal-title":"J Pain Symptom Manag"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X80486","article-title":"The effect of mirtazapine in patients with chronic pain and concomitant depression","volume":"22","author":"Freynhagen R","year":"2006","unstructured":"Freynhagen R, Muth-Selbach U, Lipfert P, Stevens MF, Zacharowski K, T\u00f6lle TR, von Giesen HJ. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin. 2006, 22:257-64. 10.1185\/030079906X80486","journal-title":"Curr Med Res Opin"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.77","article-title":"Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies","volume":"84","author":"Palmer S","year":"2013","unstructured":"Palmer S, Vecchio M, Craig JC, et al.. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013, 84:179-91. 10.1038\/ki.2013.77","journal-title":"Kidney Int"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00040107","article-title":"Depression and anxiety in urban hemodialysis patients","volume":"2","author":"Cukor D","year":"2007","unstructured":"Cukor D, Coplan J, Brown C, et al.. Depression and anxiety in urban hemodialysis patients. Clin J Am Soc Nephrol. 2007, 2:484-90. 10.2215\/CJN.00040107","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref27","article-title":"Mirtazapine","author":"Jilani TN","year":"2023","unstructured":"Jilani TN, Gibbons JR, Faizy RM, et al.. Mirtazapine. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2004.09.019","article-title":"Effects of hemodialysis on protein metabolism","volume":"15","author":"Ikizler TA","year":"2005","unstructured":"Ikizler TA. Effects of hemodialysis on protein metabolism. J Ren Nutr. 2005, 15:39-43. 10.1053\/j.jrn.2004.09.019","journal-title":"J Ren Nutr"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14660","article-title":"The effect of acute sleep deprivation on skeletal muscle protein synthesis and the hormonal environment","volume":"9","author":"Lamon S","year":"2021","unstructured":"Lamon S, Morabito A, Arentson-Lantz E, et al.. The effect of acute sleep deprivation on skeletal muscle protein synthesis and the hormonal environment. Physiol Rep. 2021, 9:e14660. 10.14814\/phy2.14660","journal-title":"Physiol Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005020157","article-title":"Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients","volume":"16","author":"Weisbord SD","year":"2005","unstructured":"Weisbord SD, Fried LF, Arnold RM, Fine MJ, Levenson DJ, Peterson RA, Switzer GE. Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol. 2005, 16:2487-94. 10.1681\/ASN.2005020157","journal-title":"J Am Soc Nephrol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.15171\/jrip.2017.09","article-title":"Incidence and severity of nausea and vomiting in a group of maintenance hemodialysis patients","volume":"6","author":"Asgari MR","year":"2017","unstructured":"Asgari MR, Asghari F, Ghods AA, Ghorbani R, Hoshmand Motlagh N, Rahaei F. Incidence and severity of nausea and vomiting in a group of maintenance hemodialysis patients. J Renal Inj Prev. 2017, 6:49-55. 10.15171\/jrip.2017.09","journal-title":"J Renal Inj Prev"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12000","article-title":"Prevalence of gastrointestinal and psychosomatic symptoms among Asian patients undergoing regular hemodialysis","volume":"18","author":"Chong VH","year":"2013","unstructured":"Chong VH, Tan J. Prevalence of gastrointestinal and psychosomatic symptoms among Asian patients undergoing regular hemodialysis. Nephrology (Carlton). 2013, 18:97-103. 10.1111\/nep.12000","journal-title":"Nephrology (Carlton)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.03.015","article-title":"Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting","volume":"30","author":"Pae CU","year":"2006","unstructured":"Pae CU. Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. Prog Neuropsychopharmacol Biol Psychiatry. 2006, 30:1143-5. 10.1016\/j.pnpbp.2006.03.015","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1381\/0960892053923923","article-title":"Mirtazapine (Remeron\u2122) as treatment for non-mechanical vomiting after gastric bypass","volume":"15","author":"Teixeira FV","year":"2005","unstructured":"Teixeira FV, Novaretti TMS, Pilon B. Mirtazapine (Remeron\u2122) as treatment for non-mechanical vomiting after gastric bypass. Obes Surg. 2005, 15:707-9. 10.1381\/0960892053923923","journal-title":"Obes Surg"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.1078","article-title":"Efficacy of mirtazapine in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: an open-label, randomized, multicenter phase III trial","volume":"36","author":"Cao J","year":"2018","unstructured":"Cao J, Wang B, Wang Z, et al.. Efficacy of mirtazapine in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: an open-label, randomized, multicenter phase III trial. J Clin Oncol. 2018, 36:10.1200\/JCO.2018.36.15_suppl.1078","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S125743","article-title":"Mirtazapine for symptom control in refractory gastroparesis","volume":"11","author":"Malamood M","year":"2017","unstructured":"Malamood M, Roberts A, Kataria R, Parkman HP, Schey R. Mirtazapine for symptom control in refractory gastroparesis. Drug Des Devel Ther. 2017, 11:1035-41. 10.2147\/DDDT.S125743","journal-title":"Drug Des Devel Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/nu9030208","article-title":"Protein nutrition and malnutrition in CKD and ESRD","volume":"9","author":"Zha Y","year":"2017","unstructured":"Zha Y, Qian Q. Protein nutrition and malnutrition in CKD and ESRD. Nutrients. 2017, 9:208. 10.3390\/nu9030208","journal-title":"Nutrients"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e32832c7ae1","article-title":"Malnutrition and wasting in renal disease","volume":"12","author":"Muscaritoli M","year":"2009","unstructured":"Muscaritoli M, Molfino A, Bollea MR, Fanelli FR. Malnutrition and wasting in renal disease. Curr Opin Clin Nutr Metab Care. 2009, 12:378-83. 10.1097\/MCO.0b013e32832c7ae1","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/648045","article-title":"Chronic renal failure, cachexia, and ghrelin","author":"Laviano A","year":"2010","unstructured":"Laviano A, Krznaric Z, Sanchez-Lara K, Preziosa I, Cascino A, Rossi Fanelli F. Chronic renal failure, cachexia, and ghrelin. Int J Pept. 2010, 648045. 10.1155\/2010\/648045","journal-title":"Int J Pept"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2010.09.003","article-title":"Appetite and gastrointestinal symptoms in chronic hemodialysis patients","volume":"21","author":"Bossola M","year":"2011","unstructured":"Bossola M, Luciani G, Rosa F, Tazza L. Appetite and gastrointestinal symptoms in chronic hemodialysis patients. J Ren Nutr. 2011, 21:448-54. 10.1053\/j.jrn.2010.09.003","journal-title":"J Ren Nutr"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5232","article-title":"Mirtazapine as appetite stimulant in patients with non-small cell lung cancer and anorexia: a randomized clinical trial","volume":"10","author":"Arrieta O","year":"2024","unstructured":"Arrieta O, C\u00e1rdenas-Fern\u00e1ndez D, Rodriguez-Mayoral O, et al.. Mirtazapine as appetite stimulant in patients with non-small cell lung cancer and anorexia: a randomized clinical trial. JAMA Oncol. 2024, 10:305-14. 10.1001\/jamaoncol.2023.5232","journal-title":"JAMA Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143588","article-title":"Mirtazapine versus megestrol in the treatment of anorexia-cachexia syndrome in patients with advanced cancer: a randomized, double-blind, controlled phase II clinical trial","volume":"15","author":"Almeida OL","year":"2023","unstructured":"Almeida OL, Ferriolli E, Taveira RC, et al.. Mirtazapine versus megestrol in the treatment of anorexia-cachexia syndrome in patients with advanced cancer: a randomized, double-blind, controlled phase II clinical trial. Cancers (Basel). 2023, 15:10.3390\/cancers15143588","journal-title":"Cancers (Basel)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.4088\/pcc.v08n0310b","article-title":"Mirtazapine therapy for dysgeusia in an elderly patient","volume":"8","author":"Padala KP","year":"2006","unstructured":"Padala KP, Hinners CK, Padala PR. Mirtazapine therapy for dysgeusia in an elderly patient. Prim Care Companion J Clin Psychiatry. 2006, 8:178-80. 10.4088\/pcc.v08n0310b","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-023-03176-4","article-title":"Exploration of symptom clusters during hemodialysis and symptom network analysis of older maintenance hemodialysis patients: a cross-sectional study","volume":"24","author":"Zhou M","year":"2023","unstructured":"Zhou M, Gu X, Cheng K, Wang Y, Zhang N. Exploration of symptom clusters during hemodialysis and symptom network analysis of older maintenance hemodialysis patients: a cross-sectional study. BMC Nephrol. 2023, 24:115. 10.1186\/s12882-023-03176-4","journal-title":"BMC Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/289253-mirtazapine-a-one-drug-intervention-for-the-physical-and-psychological-symptoms-of-end-stage-renal-disease-esrd","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T14:28:20Z","timestamp":1728916100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/289253-mirtazapine-a-one-drug-intervention-for-the-physical-and-psychological-symptoms-of-end-stage-renal-disease-esrd"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.71439","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}